{"slideshow_credits": null, "snippet": "About one-third of American adults are obese, so a successful weight loss drug could potentially have huge sales.", "abstract": "Food and Drug Administration approves Contrave, third new prescription drug for obesity since 2012, developed by Orexigen Therapeutics; drug will be marketed by Takeda Pharmaceutical of Japan.", "section_name": "Business Day", "print_page": "3", "document_type": "article", "byline": {"person": [{"firstname": "Andrew", "role": "reported", "lastname": "POLLACK", "rank": 1, "organization": ""}], "original": "By ANDREW POLLACK", "contributor": ""}, "web_url": "http://www.nytimes.com/2014/09/11/business/new-drug-to-treat-obesity-gains-approval-by-fda.html", "lead_paragraph": "About one-third of American adults are obese, so a successful weight loss drug could potentially have huge sales.", "headline": {"main": "New Drug to Treat Obesity Gains Approval by F.D.A.", "print_headline": "New Drug to Treat Obesity Gains Approval by F.D.A."}, "_id": "5410f7f638f0d80f29521f9d", "word_count": "500", "multimedia": [], "pub_date": "2014-09-11T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"value": "Obesity", "name": "subject", "is_major": "Y", "rank": "1"}, {"value": "Orexigen Therapeutics Inc", "name": "organizations", "is_major": "Y", "rank": "2"}, {"value": "Takeda Pharmaceutical", "name": "organizations", "is_major": "Y", "rank": "3"}, {"value": "Diet and Nutrition", "name": "subject", "is_major": "N", "rank": "4"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "N", "rank": "5"}, {"value": "Food and Drug Administration", "name": "organizations", "is_major": "Y", "rank": "6"}], "blog": [], "subsection_name": null, "type_of_material": "News"}